Perrigo Company plc

PRGO ·Healthcare, Drug Manufacturers - General, Ireland
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012
Operating Activities
Net Income $119.6M $-4.01B $136.1M $232.8M $441.9M $401.6M
Depreciation & Amortization $444.8M $457.0M $258.7M $206.1M $160.2M $135.3M
Depreciation $95.2M $100.2M $84.3M $77.9M $66.2M $58.2M
Amortization $349.6M $356.8M $174.5M $128.2M $94.0M $74.8M
Stock-Based Compensation $43.8M $23.0M $31.6M $24.6M $18.4M $19.0M
Net Cash from Operating Activities $698.9M $654.9M $855.2M $633.0M $553.8M $513.4M
Investing Activities
Capital Expenditures $88.6M $106.2M $137.0M $171.6M $104.1M $120.2M
Business Acquisitions $400.0K $427.4M $2.18B $1.61B $852.3M $582.3M
Net Cash from Investing Activities $2.34B $-175.0M $-2.30B $-1.64B $-947.8M $-684.1M
Financing Activities
Dividends Paid $91.1M $83.2M $64.8M $46.1M $33.0M $29.0M
Stock Repurchases $191.5M $0 $0 $0 $0 $8.2M
Net Cash from Financing Activities $-3.00B $-268.7M $1.52B $1.03B $577.2M $458.7M
Net Change in Cash $56.4M $204.5M $-13.9M $19.6M $177.4M $292.4M
Free Cash Flow $610.3M $548.7M $718.2M $461.4M $449.7M $393.2M
← Newer Page 2 of 2 Older →